Fluconax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluconax

What is Fluconax?

Fluconax is a pharmaceutical formulation containing fluconazole, a synthetic compound belonging to the triazole class of antifungal agents. It is primarily utilized in medical practice to address a broad spectrum of fungal infections by inhibiting the growth and reproduction of the causative organisms.

Therapeutic Mechanism

The active ingredient, fluconazole, works by interfering with the fungal synthesis of ergosterol. Ergosterol is a vital component of the fungal cell membrane; by disrupting its production, the medication compromises the integrity of the cell wall, leading to increased permeability and the eventual cessation of fungal growth.

Clinical Applications

Fluconax is indicated for various fungal conditions, ranging from localized mucosal infections to systemic issues. Its common applications include:

  • Yeast Infections: Often used for infections involving the Candida species, such as oral thrush or vaginal yeast infections.
  • Dermatological Infections: Applied in cases of fungal skin conditions, including ringworm, athlete's foot, and jock itch.
  • Systemic Mycoses: Utilized for more serious internal infections, such as cryptococcal meningitis or systemic candidiasis, particularly in individuals with compromised immune systems.

Pharmacological Profile

Fluconax is characterized by its high bioavailability and its ability to penetrate various body fluids and tissues. This distribution profile allows it to be effective against fungal pathogens located in different parts of the body. Once administered, the medication is primarily excreted through the kidneys in its unchanged form.

Regulatory References

  1. Fluconazole: MedlinePlus Drug Information

What side effects are possible with Fluconax?

Possible Side Effects and Safety Information

The safety profile of Fluconax (Fluconazole) ranges from commonly reported, generally mild adverse events to rare, serious systemic risks, as documented by regulatory authorities. Every patient should be monitored for signs of severe reactions.


Adverse Reaction Profile

Common Adverse Reactions ( geq 1%):

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.
  • Nervous System: Headache, dizziness.
  • Other: Rash, elevated liver enzymes.

Serious and Clinically Significant Reactions (Rare):

Fluconax is associated with a risk of serious hepatic toxicity, including liver failure (which may be fatal), and severe exfoliative cutaneous reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. It may also cause QT interval prolongation on an electrocardiogram, which can lead to the life-threatening heart arrhythmia Torsade de Pointes. Immediate discontinuation of the drug is required if signs of these serious events occur.


Safety Considerations and Restrictions

Pregnancy Warning:

Use of chronic, high-dose Fluconax (400–800 mg/day) during the first trimester of pregnancy has been linked to a rare and distinct pattern of congenital abnormalities. Furthermore, studies have suggested an increased risk of spontaneous abortion and cardiac malformations following exposure to any dose during early pregnancy. The drug is contraindicated with the concomitant use of medications known to prolong the QT interval and metabolized by the CYP3A4 enzyme (e.g., cisapride, pimozide). Caution is required in patients with pre-existing heart, liver, or kidney problems and those with electrolyte abnormalities.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a fluconazole overdose as being associated with specific changes in mental state and consciousness, which necessitate immediate emergency action.

Documented Overdose Manifestations

Reports of overdose have been accompanied by serious central nervous system effects, including hallucination and paranoid behavior.

Emergency Actions and Clinical Management

In the event of a known or suspected overdose, immediate emergency medical help must be sought. If the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened, emergency services should be contacted without delay.

Otherwise, for overdose situations without these critical symptoms, the national Poison Control helpline should be called for immediate guidance.

Clinical management in a healthcare setting is symptomatic and involves supportive measures. If clinically indicated, procedures such as gastric lavage may be performed to manage the ingestion. Due to the drug's high excretion through the kidneys, hemodialysis is an effective intervention; a three-hour session is documented to reduce the plasma concentration by approximately fifty percent.

Therapeutic Uses of Fluconax

What Fluconax Treats: Main Uses and Benefits

Fluconax (Fluconazole) is commonly prescribed to address a wide range of fungal and yeast infections, focusing on symptom relief and managing the underlying pathogen. Its therapeutic value generally spans from common, localized discomfort to conditions marked by increased systemic burden, and may provide supportive therapeutic benefit across diverse patient groups. The medication is used for infections of the vagina, mouth, throat, and more serious infections involving the blood and nervous system.

The main therapeutic domains for Fluconax include managing systemic infections such as candidemia, addressing CNS mycoses like Cryptococcal Meningitis, and is relevant for managing symptomatic mucosal candidiasis of the mouth, esophagus, and vaginal area.


Managing Symptomatic Infections and Relapse Risk

This medication may provide support in clinical settings marked by severe patient distress, and is relevant in situations involving recurrent or episodic manifestations. It helps address symptom intensity and supports the easing of the overall symptom load of mucosal discomfort, including painful swallowing, intense burning, and persistent itching. Furthermore, it is commonly used to assist with managing the risk of recurrence (relapse) of serious fungal diseases.

“Fluconax is considered relevant for easing symptoms that interfere with daily comfort, supporting patients through both acute and recurrent episodes of fungal disease.”


Quick Fact: Relief for Mucosal Discomfort

  • Target Symptoms: Painful swallowing, genital burning, itching, and the discomfort associated with white patches (plaque formations) from thrush.
  • Core Benefit: Provides support that helps ease the overall symptom burden during difficult episodes and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile

Fluconax (Fluconazole) eligibility is strictly defined by regulatory bodies. The medication is contraindicated in patients with a known hypersensitivity to fluconazole or other azole antifungals. Absolute prohibitions also exist against its use with specific QT-prolonging medications, such as cisapride and high-dose terfenadine.

Use is established across a broad age range, including adults and pediatric patients (infants and children). However, caution is advised for older adults due to the likelihood of decreased kidney function.

Eligibility is restricted based on existing medical conditions. Use requires careful monitoring in patients with pre-existing hepatic (liver) dysfunction or renal (kidney) impairment, as these conditions affect how the body processes the medicine. Further caution is necessary for individuals with proarrhythmic cardiac conditions or electrolyte abnormalities like low potassium.

Regarding physiological states, high-dose or prolonged use is contraindicated during pregnancy unless the infection is life-threatening. Use is also not recommended for women who are breastfeeding if repeated or high doses are required.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Fluconax (fluconazole) is a potent inhibitor of cytochrome P450 (CYP) isoenzymes, particularly CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This mechanism leads to increased plasma concentrations of many co-administered medicinal products metabolized by these enzymes, which can increase the risk of adverse effects.

Contraindicated Combinations

Concomitant use is prohibited due to the risk of serious cardiotoxicity or elevated drug exposure when combined with: Cisapride, Astemizole, Pimozide, and Quinidine. The co-administration with Terfenadine is also prohibited when Fluconax is used at doses of 400 mg per day or higher.

Required Monitoring and Dose Adjustments

Close monitoring is required with many drugs, including Oral Anticoagulants (e.g., Warfarin, requiring INR monitoring), Statins (e.g., Atorvastatin, Simvastatin, requiring monitoring for myopathy), Oral Hypoglycemics (e.g., Sulfonylureas, requiring blood glucose monitoring), and Immunosuppressants (e.g., Cyclosporine, Tacrolimus, requiring drug level monitoring).

Coadministration with Voriconazole is not recommended due to a significant increase in Voriconazole exposure. The enzyme-inhibiting effect of Fluconax persists for approximately four to five days after treatment is discontinued due to its long half-life. Patients on high doses (400 to 800 mg/day) who are women of child-bearing potential should use effective contraception during treatment and for about one week after the final dose.

Mechanism of Action

Fluconax (Fluconazole) acts by disrupting the fungal cell's structural integrity through selective enzyme inhibition. The molecule targets the fungal enzyme Lanosterol 14-alpha-demethylase ( CYP51), a key component in the fungal Cytochrome P450 system. The drug binds covalently to the heme iron center of the enzyme, rendering it inactive.

This inhibition blocks the ergosterol biosynthesis pathway, resulting in a critical depletion of ergosterol, the primary sterol component of the fungal cell membrane. Simultaneously, toxic intermediate sterols, primarily 14alpha-methylsterols, accumulate within the membrane. This dual mechanistic cascade creates a structurally compromised and hyper-permeable membrane, leading to impaired regulation of internal stability and function. The resulting cellular fragility contributes to the suppression of fungal proliferation and the cessation of growth.

The efficacy of this mechanism is subject to biological constraints, such as the overexpression of fungal efflux pumps (e.g., Cdr1), which actively reduce the intracellular concentration of Fluconazole needed for full CYP51 inhibition.

Dosage and Administration Information

Official Administration Protocol

Fluconax (Fluconazole) is officially administered via the oral route (capsules, tablets, or suspension) or as an intravenous (IV) infusion. The daily dose is considered interchangeable between the two administration methods.


Dosing Regimens and Frequency

Dosing is dictated by the specific type of infection. Serious systemic conditions often commence with a high loading dose on Day 1 (up to 800 mg), followed by a standard once-daily maintenance dose typically ranging from 100 mg to 400 mg. For acute, localized conditions like vaginal candidiasis, the standard is a single oral dose of 150 mg. The duration of use is highly variable, ranging from a single day to six months or more for long-term suppressive therapy.


Administration Conditions and Adjustments

Oral forms of Fluconax may be taken with or without food. For the intravenous route, official procedural constraints mandate that the solution must be administered via slow infusion, with the rate not exceeding 200 mg per hour. A critical instruction for maintenance therapy specifies that the dose should be reduced by 50% for adult patients with confirmed renal impairment (Creatinine Clearance le 50 mL/min), after the initial loading dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Fluconax (Fluconazole)

This overview describes the types of clinical studies that have been conducted to evaluate Fluconax (fluconazole), the research populations they included, and what findings have been reported by regulatory bodies and scientific literature. The purpose of this summary is to describe what the evidence suggests, but it does not offer any clinical advice or interpretation.


Evidence for use in Systemic Fungal Infections

Research examined the use of Fluconax in conditions where fungal infections have spread throughout the body. The evidence includes Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that involved comparisons to other treatment approaches. Studies monitored the rate of mycological clearance and patient status as defined by pre-specified clinical endpoints. Findings describe patterns observed in these studies related to the measurements taken of the infection status. Certainty remains low regarding the research for some types of fungi, such as Candida glabrata strains.


Evidence for use in Mucosal and Localized Candidiasis

Studies explored Fluconax for infections like thrush and vaginal yeast infections. The research base involves RCTs that monitored outcomes related to physical discomfort. These trials assessed symptom patterns, focusing on clinical endpoints (defined as changes in lesions and symptoms) and organism clearance measurements.


Evidence for Prevention in High-Risk Groups

Fluconax was evaluated in RCTs focused on preventing fungal infections in people known to be at high risk (e.g., transplant patients, low birth weight infants). Research describes patterns observed in the studies, suggesting that infection occurrence was measured differently in the exposed population during the high-risk periods. The potential for prophylactic use to increase the prevalence of drug-resistant fungal strains is a subject monitored in scientific literature.


Research Gaps and Uncertainties

For many indications, follow-up durations were limited, meaning there is insufficient information for long-term outcomes, such as sustained symptom resolution. Data for certain subgroups, particularly non-HIV immunocompromised patients, are limited. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Fluconazole - StatPearls - NCBI Bookshelf (Review of Indications and Evidence)
  2. High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals (RCT Protocol Summary)
  3. RECOMMENDATIONS ON INDUCTION, CONSOLIDATION AND MAINTENANCE ANTIFUNGAL TREATMENT REGIMENS - Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV (WHO Guideline)

Frequently Asked Questions (FAQ)

Common questions about Fluconax (FAQ)

Q: How quickly does Fluconax typically start to work after the first dose?

A: Official pharmacokinetic studies indicate that Fluconax reaches its maximum concentration in the bloodstream approximately 3 hours after a dose. If a higher initial dose is administered, the concentration in the body can be close to the stable, intended level (steady-state) by the second day of treatment. This information describes how quickly the medicine enters the system.

Q: Can Fluconax be taken at the same time as common over-the-counter pain relievers?

A: Regulatory guidance suggests that Fluconax may interact with nonsteroidal anti-inflammatory drugs (NSAIDs), which includes common pain relievers like ibuprofen or naproxen. Because of the potential for increased drug exposure, official sources note that consultation with a healthcare provider regarding the use of any OTC pain reliever is appropriate.

Q: Is it okay to drive or operate machinery after taking Fluconax?

A: Official product information states that Fluconax may cause certain central nervous system effects, such as dizziness or seizures, as rare side effects. Due to these possibilities, the presence of these effects may influence the ability to safely perform activities that require concentration, such as driving or operating machinery.

Q: Do studies show that Fluconax has an effect on hormonal birth control?

A: Studies have shown that Fluconax may change the level of active ingredients found in oral contraceptives, such as ethinyl estradiol and norethindrone, within the blood. This alteration in drug levels may lead to symptoms like nausea, vomiting, or vaginal bleeding in some individuals.

Q: What are the restrictions on drinking alcohol while taking Fluconax?

A: Official product documents do not list a direct pharmacological interaction between Fluconax and alcohol. However, Fluconax is associated with a risk of serious liver toxicity, and official warnings describe the need for caution in patients with pre-existing liver conditions. Due to this concern, some sources indicate that the use of alcohol may be restricted.

Q: Can the medication affect the results of any standard laboratory tests?

A: Fluconax can cause elevations in standard blood tests for liver function, such as AST, ALT, and Alkaline Phosphatase. The medication may also be associated with changes in blood components like anemia. For individuals taking blood thinners, Fluconax can also influence the results of the monitoring test (INR).

Q: Do official documents mention any effects of Fluconax on fertility?

A: There is a lack of published human studies to confirm the effects of Fluconax on fertility in males. Evidence from animal studies indicated that exposure was associated with a temporary decrease in sperm count, which returned to normal levels after the medication was stopped.

Q: What does the term 'systemic exposure' mean in relation to Fluconax?

A: Systemic exposure is a medical term that simply refers to the amount of medicine circulating in the bloodstream (plasma) and distributed throughout the body's tissues. This broad distribution is what allows Fluconax to treat infections that have spread beyond the initial site, such as into the blood or organs.

Q: What does regulatory information say about the interaction between Fluconax and grapefruit juice?

A: The official prescribing information for Fluconax does not list grapefruit juice as a specific substance known to affect the absorption or metabolism of the drug. This information is noted because certain other medications are known to be affected by grapefruit juice consumption.

Q: What are the general expectations for follow-up care when using Fluconax?

A: General follow-up expectations often involve watching for any signs of serious side effects, such as liver problems or severe skin reactions. Furthermore, patients taking certain interacting medications, like blood thinners or statins, often require specific blood monitoring during the course of treatment.

Q: Is it described in official sources that Fluconax can cause vision changes?

A: Official adverse event reporting includes rare side effects involving the eyes and nervous system. These reports have included serious symptoms such as sudden vision loss, blurred vision, and visual field defects.

Q: What are the informational descriptions about combining Fluconax with herbal supplements?

A: Official medical guidance typically emphasizes caution regarding the use of herbal remedies or dietary supplements while taking Fluconax. This is because these products are generally not included in the required testing for drug interactions and may unpredictably affect how the body handles the medication.

Q: Is the medication Fluconax gluten-free, or does it contain common allergens?

A: Official documentation concerning the ingredients of Fluconax indicates that certain oral forms contain excipients such as lactose (in capsules) or sucrose (in the oral suspension powder). This ingredient information may be relevant for patients with specific inherited intolerances to sugar.

Q: What does the term 'contraindication' mean in the context of Fluconax use?

A: In the context of Fluconax, a contraindication is a regulatory classification defining situations in which the medicine must be withheld or not administered. This prohibition exists because the combination presents a high, unacceptable risk of serious harm, such as a severe allergic reaction or life-threatening heart rhythm issue.

Q: What are informational descriptions about Fluconax's use with other anti-infective agents?

A: Regulatory documents describe situations where combining Fluconax with certain other anti-infective medications is not recommended or is prohibited. For instance, co-administration with the antibiotic Erythromycin or the antifungal Voriconazole is either not recommended or contraindicated due to the increased possibility of serious adverse effects.

Q: What information is available about accidental overdose of Fluconax?

A: Regulatory reports describing accidental overdose of Fluconax have noted symptoms involving the nervous system, such as hallucination and paranoid behavior. Official information states that the approach to managing an overdose typically consists of symptomatic treatment and supportive measures. It is noted that standard hemodialysis can remove approximately 50% of the drug from the body over a three-hour period.

How should Fluconax be stored and disposed of?

How to Store and Dispose of Fluconax?

Storage Requirements

Fluconax must be stored according to its specific formulation to maintain stability. The tablets and dry powder for oral suspension should be kept below 30 C (86 F). The reconstituted oral suspension and intravenous solution require temperature control and must be protected from freezing. Keep all forms in the original, tightly closed container to protect the product from moisture.

Handling and Protection

Discard any unused portion of the reconstituted oral suspension after 14 days (2 weeks). It is essential that all forms of this medication are stored out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

When disposing of Fluconax that is expired or no longer needed, do not flush it down a toilet unless specifically instructed to do so. Follow official governmental disposal guidelines, typically by using a medicine take-back program or mixing the medication with an undesirable substance, sealing it in a plastic bag, and discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluconax found in:

A-Z Index: